The HOPE Biobank Resource (BMT CTN 2402 HOPE)
Part of paid clinical trials in Gainesville, Florida.
- Sponsor
- Medical College of Wisconsin
- Study ID
- NCT07227155
- Status
- Recruiting
Conditions
- Aplastic Anemias
- Bone Marrow Failure
- Hemoglobinopathies
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Accepted
Study Details
A prospective, multicenter study that will establish a repository of biospecimens and clinical data from patients undergoing hematopoietic stem cell transplant (HCT) or gene therapy (GT) for treatment of non-malignant blood diseases.
Key Dates
- Start date
- May 15, 2026
- Status verified
- Jun 2026
- Primary completion
- Mar 30, 2031
- Completion
- Mar 30, 2031
Study Design
- Enrollment
- 375 participants (estimated)
Primary Outcome Measure
Develop a biorepository that will establish mechanistic insights and biologic correlates to key casues of fialure of HCT and GT for Non-malignant Diseases (NMD). [ Time Frame: 5 Years ]
Central Contacts
- Megan Scott301-251-1161
Locations (6)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Florida | Gainesville | Florida | 32611 | Jordan Milner, MD (PRINCIPAL_INVESTIGATOR) |
| Oregon Health and Science University | Portland | Oregon | 97239 | Evan Shereck, MD (PRINCIPAL_INVESTIGATOR) |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37235 | Jim Connelly, MD (PRINCIPAL_INVESTIGATOR) |
| Baylor College of Medicine | Houston | Texas | 77030 | Alexander Ngwube, MD (PRINCIPAL_INVESTIGATOR) |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Neel Bhatt, MD (PRINCIPAL_INVESTIGATOR) |
| Children's Hospital of Wisconsin | Milwaukee | Wisconsin | 53226 | Julie Talano, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Gainesville, FL
Related Studies
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant DiseasesPHASE1/PHASE2 · Recruiting · Washington University School of Medicine · Phoenix, Arizona
- A Long-term Follow-up Study in Participants Who Received CTX001PHASE3 · Enrolling By Invitation · Vertex Pharmaceuticals Incorporated · Palo Alto, California
- Discarded Bone Marrow for Hematology ResearchRecruiting · St. Jude Children's Research Hospital · Memphis, Tennessee
- Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell DiseasePHASE3 · Recruiting · Vertex Pharmaceuticals Incorporated · New York, New York